Is the Availability of Biosimilar Adalimumab Associated with Budget Savings? A Difference-in-Difference Analysis of 14 Countries.

Published in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2023)

The availability of biosimilars was associated with a decrease in adalimumab expenditure without compromising the consumption of adalimumab.

Keyphrases